On April 24th 2018, the Magdeburger MIRACUM partner site organised the first workshop “Molecular Tumour Boards”, which refers to our Use Case 3 “From Knowledge to Action – Support for Molecular Tumour Boards”. Magdeburg welcomed participants from Erlangen, Frankfurt, Freiburg and of course Magdeburg. In addition, many MIRACUM members followed the presentations via webconference. The presenters gave a wide range of topics from experiences with tumour boards at the university hospitals in Erlangen and Freiburg, about the use of different molecular proceedings and international, informatical support tools that are already applied.
List of speakers:
Tumorboards am Universitätsklinikum Freiburg: Management und Dokumentation
PD Dr. med. Martin Boeker, MME, MCSc
Institute of Medical Biometry and Statistics, Albert-Ludwigs University Freiburg
Analyse und Integration von Sequenzierungsdaten im Rahmen des Molekularen Tumorboard
Dr. med. Dr. phil. Melanie Börries
Institute of Molecular Medicine and Cell Research, Albert-Ludwigs University Freiburg
Unterstützung des Molekularen Tumorboards durch cBioPortal – aktueller Stand und geplante MIRACUM-Anpassungen
Jan Christoph, M.Sc., M.Sc.
Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-Nürnberg
Molekulares Tumorboard am CCC-EMN > Erlangen: ein 2-Jahres-Bericht
Dr. med. Markus Eckstein
Diagnostic Molecular Pathology, University Hospital Erlangen
3D-Zellkultur für personalisierte Onkologie
Prof. Dr. med. univ. rer. Dr. sc. nat. Johannes Haybäck
Institute of Pathology, University Hospital Magdeburg
Die Rolle von humoralen Tumormarkern im Bereich des Molekularen Tumorboards
Dr. rer. nat. Juliane Hoffmann
Institute of Clinical Chemistry and Pathobiochemistry, University Hospital Magdeburg
Möglichkeiten und Herausforderungen eines MTBs aus Sicht der Molekularpathologie
Prof. Dr. Silke Laßmann (BSc., PhD); M.A.
Institute of Clinical Pathology, University Hospital Freiburg
Molecular Tumor Boards: an immunologists perspective
Prof. Dr. med. Thomas Tüting
University Dermatological Clinic Magdeburg
Präzisionsonkologie und molekulare Tumorboards – Chancen und Herausforderungen
Dr. med. Sebastian Wagner
University Cancer Center, University Hospital Frankfurt
On April 24th 2018, the Magdeburger MIRACUM partner site organised the first workshop “Molecular Tumour Boards”, which refers to our Use Case 3 “From Knowledge to Action – Support for Molecular Tumour Boards”. Magdeburg welcomed participants from Erlangen, Frankfurt, Freiburg and of course Magdeburg. In addition, many MIRACUM members followed the presentations via webconference. The presenters gave a wide range of topics from experiences with tumour boards at the university hospitals in Erlangen and Freiburg, about the use of different molecular proceedings and international, informatical support tools that are already applied.
List of speakers:
Tumorboards am Universitätsklinikum Freiburg: Management und Dokumentation
PD Dr. med. Martin Boeker, MME, MCSc
Institute of Medical Biometry and Statistics, Albert-Ludwigs University Freiburg
Analyse und Integration von Sequenzierungsdaten im Rahmen des Molekularen Tumorboard
Dr. med. Dr. phil. Melanie Börries
Institute of Molecular Medicine and Cell Research, Albert-Ludwigs University Freiburg
Unterstützung des Molekularen Tumorboards durch cBioPortal – aktueller Stand und geplante MIRACUM-Anpassungen
Jan Christoph, M.Sc., M.Sc.
Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-Nürnberg
Molekulares Tumorboard am CCC-EMN > Erlangen: ein 2-Jahres-Bericht
Dr. med. Markus Eckstein
Diagnostic Molecular Pathology, University Hospital Erlangen
3D-Zellkultur für personalisierte Onkologie
Prof. Dr. med. univ. rer. Dr. sc. nat. Johannes Haybäck
Institute of Pathology, University Hospital Magdeburg
Die Rolle von humoralen Tumormarkern im Bereich des Molekularen Tumorboards
Dr. rer. nat. Juliane Hoffmann
Institute of Clinical Chemistry and Pathobiochemistry, University Hospital Magdeburg
Möglichkeiten und Herausforderungen eines MTBs aus Sicht der Molekularpathologie
Prof. Dr. Silke Laßmann (BSc., PhD); M.A.
Institute of Clinical Pathology, University Hospital Freiburg
Molecular Tumor Boards: an immunologists perspective
Prof. Dr. med. Thomas Tüting
University Dermatological Clinic Magdeburg
Präzisionsonkologie und molekulare Tumorboards – Chancen und Herausforderungen
Dr. med. Sebastian Wagner
University Cancer Center, University Hospital Frankfurt